An interventional study of anesthesia without opioids in Analgesics, Opioid, Anesthesia, Endotracheal and Anesthesia, General, sponsored by Jagiellonian University. Recruiting at 1 site in Poland. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-08-26.
Sponsored by Jagiellonian University · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Opioid-free anesthesia (OFA) is a multimodal technique that eliminates intraoperative opioids by combining dexmedetomidine, ketamine, lidocaine, NSAIDs, and regional analgesia. Growing evidence suggests OFA reduces postoperative opioid consumption, opioid-related adverse effects, and may have favorable oncological implications in cancer surgery.
This randomized controlled trial compares OFA with opioid-based anesthesia (remifentanil) in patients undergoing elective urological surgery: laparoscopic nephrectomy, robotic nephrectomy, laparoscopic prostatectomy, robotic prostatectomy, laparoscopic cystectomy, and robotic cystectomy.
The PRIMARY OBJECTIVE is to compare the total postoperative oxycodone dose (mg) administered via patient-controlled analgesia (PCA) during the first 24 hours after surgery between the OFA and remifentanil groups.
SECONDARY OBJECTIVES include: postoperative pain intensity (NRS) at 1, 2, 6, 12, and 24 hours; incidence of postoperative nausea and vomiting (PONV); change in serum creatinine from baseline to postoperative day 1; change in white blood cell (WBC) count from baseline to postoperative day 1; and the ratio of demanded to delivered PCA boluses.
PRE-SPECIFIED SUBGROUP ANALYSES will compare outcomes by surgical procedure type: laparoscopic nephrectomy, robotic nephrectomy, laparoscopic prostatectomy, robotic prostatectomy, laparoscopic cystectomy, and robotic cystectomy. Subgroup-by-treatment interaction tests will be performed and reported as forest plots.
Planned enrollment: approximately 600 patients (300 per arm). Follow-up: 24 hours postoperatively.
All consecutive patients undergoing elective urological surgery (laparoscopic or robotic nephrectomy, prostatectomy, or cystectomy) will be randomly divided into two groups: one under completely opioid-free anesthesia (infusion of ketamine, lidocaine and dexmedetomidine, with inhalation of sevoflurane) and the other under combined general anesthesia (using an infusion of remifentanil intraoperatively). In the postoperative period, all patients will receive oxycodone in a PCA pump or in the form of oral tablets [oxycodone hydrochloride + naloxone hydrochloride] and co-analgesics in the form of paracetamol and metamizole.
Opioid-free general anesthesia is a recognized method used during anesthesia. It allows participants to effectively control pain, reducing the number of complications associated with taking large doses of opioid drugs. It should be emphasized that it is approved for use in routine anesthetic practice, and whether such a technique is used in a given patient depends on the experience, knowledge and preferences of the anesthesiologist. It is used in everyday anesthetic practice, but there is no conclusive scientific data confirming its advantage in patients undergoing major urological surgery.
Mulier et al. proposed an OFA scheme including dexmedetomidine, ketamine and lidocaine for the induction of anesthesia, ensuring sedation, analgesia and sympatholytic therapy, followed by a maintenance infusion of lidocaine and dexmedetomidine. The protocol proposed by Mulier et al. is widely used and accepted worldwide. Initially used in patients undergoing bariatric procedures, it was subsequently extended to other types of surgical procedures.
In the postoperative period, pain will be assessed using the NRS scale at 1, 2, 6, 12, and 24 hours after the procedure. Serum creatinine and white blood cell (WBC) count will be measured preoperatively (baseline) and on postoperative day 1.
Jagiellonian University is the lead sponsor of 161 studies on the registry; 34 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Opioid-based general anesthesia. Premedication includes dexamethasone, paracetamol, metamizole, magnesium sulfate, and ibuprofen. Induction with propofol and rocuronium under TOF monitoring. Maintenance with sevoflurane titrated to MAC; intraoperative analgesia provided by remifentanil infusion (total intraoperative dose recorded). Regional analgesia by procedure: bilateral ESP block (nephrectomy), bilateral QL block (prostatectomy), and continuous epidural ropivacaine infusion (cystectomy). Postoperative analgesia: oxycodone PCA (2 mg bolus, 10-min lockout, no background infusion) with paracetamol and metamizole.
Opioid-free general anesthesia. Premedication includes dexamethasone, paracetamol, metamizole, magnesium sulfate, ibuprofen, and dexmedetomidine (OFA group only). Induction with propofol, ketamine (OFA group only), and rocuronium under TOF monitoring. Maintenance with sevoflurane titrated to MAC; intraoperative analgesia provided by a continuous dexmedetomidine/ketamine infusion with rescue boluses for tachycardia or hypertension. Regional analgesia by procedure: bilateral ESP block (nephrectomy), bilateral QL block (prostatectomy), and continuous epidural ropivacaine infusion (cystectomy). Postoperative analgesia: oxycodone PCA (2 mg bolus, 10-min lockout, no background infusion) with paracetamol and metamizole.
Other: anesthesia without opioids
Opioid free general anesthesia
Total postoperative oxycodone dose administered via PCA (mg)
Total postoperative oxycodone dose administered via PCA (mg) - Cumulative dose of oxycodone (mg) self-administered via PCA pump during the first 24 hours after surgery, compared between the OFA and remifentanil groups.
Time frame: 0-24 hours after surgery
Postoperative pain (NRS)
Postoperative pain intensity as assessed by the Numeric Rating Scale (NRS) - NRS (0 = no pain, 10 = worst imaginable pain) at rest, compared between groups; score reported at each time point.
Time frame: 1, 2, 6, 12, and 24 hours after surgery
Postoperative nausea and vomiting (PONV)
Number of participants with postoperative nausea and/or vomiting (PONV) - Number (and proportion) of participants with any nausea and/or vomiting within 24 h after surgery (binary: yes/no), compared between groups.
Time frame: 0-24 hours after surgery
Postoperative renal function (serum creatinine)
Change in serum creatinine from baseline to postoperative day 1 (µmol/L) - Serum creatinine (µmol/L) at baseline (preoperative) and on POD1; change from baseline compared between groups.
Time frame: Baseline and postoperative day 1
Patient-controlled analgesia (PCA) demand/administered ratio
Ratio of demanded to delivered PCA boluses - Ratio of demanded to delivered PCA bolus attempts within 24 h after surgery, compared between groups.
Time frame: 0-24 hours after surgery
Change in white blood cell (WBC) count from baseline to postoperative day 1 (×10⁹/L)
White blood cell (WBC) count (×10⁹/L) measured preoperatively (baseline) and on postoperative day 1; change from baseline compared between the OFA and remifentanil groups.
Time frame: Baseline and postoperative day 1
Plan to share: Yes — We plan to share demografic data, type of surgery, score in NRS and opioid consumption dosage.
Supporting information: Study protocol
Time frame: The data will be available in 2026 for 1 year
No publications or documents are linked to this record.
Started Apr 2024 (actual). Primary completion is estimated for Dec 2026, 32 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.